• Something wrong with this record ?

Pre-treatment with Empagliflozin ameliorates Cisplatin induced acute kidney injury by suppressing apoptosis

Maaly A. Abd Elmaaboud, Ahmed M. Kabel, Mohamed Elrashidy

. 2019 ; 17 (1) : 82-90.

Language English Country Czech Republic

Persistent link   https://www.medvik.cz/link/bmc19019281

Dose-limiting nephrotoxicity restricts Cisplatin use in high therapeutic doses. Empagliflozin showed a reno-protective effect in diabetic nephropathy. We investigated if Empagliflozin can ameliorate Cisplatin nephrotoxicity whether used prophylactically or therapeutically. Forty male Wistar rats were divided into 5 groups: (1) control; (2) Cisplatin-induced nephrotoxicity by single intraperitoneal dose; (3) Empagliflozin was given for 10 days before a single dose of Cisplatin; (4) a single dose of Cisplatin followed by Empagliflozin for 10 days; (5) received Empagliflozin only. Regular assessment of weight was done, biochemical evaluation for serum urea, creatinine, uric acid, albumin, and glucose was performed, kidney tissue nerve growth factor-β (NGF-β) and oxidative stress parameters were measured, kidneys were evaluated histopathologically and immunostained for caspase 3. Cisplatin significantly reduced body weight, NGF-β, and reduced glutathione, elevated urea, creatinine, and malondialdehyde with no effect on other serum biochemical parameters. Histopathologically, there was high acute tubular necrosis (ATN) score with strong immunostaining of caspase 3. The use of Empagliflozin significantly reduced urea and creatinine in both prophylactic and therapeutic, reduced ATN score in the prophylactic group associated with minimal staining of caspase 3 and elevated reduced glutathione. In conclusion, prophylactic Empagliflozin protected against Cisplatin-induced acute kidney injury mainly via anti-apoptotic effect.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc19019281
003      
CZ-PrNML
005      
20200114173648.0
007      
ta
008      
190601s2019 xr da f 000 0|eng||
009      
AR
024    7_
$a 10.32725/jab.2019.003 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xr
100    1_
$a Elmaaboud, Maaly A. Abd $u Tanta University, Faculty of Medicine, Department of Pharmacology, Tanta, Egypt
245    10
$a Pre-treatment with Empagliflozin ameliorates Cisplatin induced acute kidney injury by suppressing apoptosis / $c Maaly A. Abd Elmaaboud, Ahmed M. Kabel, Mohamed Elrashidy
504    __
$a Literatura
520    9_
$a Dose-limiting nephrotoxicity restricts Cisplatin use in high therapeutic doses. Empagliflozin showed a reno-protective effect in diabetic nephropathy. We investigated if Empagliflozin can ameliorate Cisplatin nephrotoxicity whether used prophylactically or therapeutically. Forty male Wistar rats were divided into 5 groups: (1) control; (2) Cisplatin-induced nephrotoxicity by single intraperitoneal dose; (3) Empagliflozin was given for 10 days before a single dose of Cisplatin; (4) a single dose of Cisplatin followed by Empagliflozin for 10 days; (5) received Empagliflozin only. Regular assessment of weight was done, biochemical evaluation for serum urea, creatinine, uric acid, albumin, and glucose was performed, kidney tissue nerve growth factor-β (NGF-β) and oxidative stress parameters were measured, kidneys were evaluated histopathologically and immunostained for caspase 3. Cisplatin significantly reduced body weight, NGF-β, and reduced glutathione, elevated urea, creatinine, and malondialdehyde with no effect on other serum biochemical parameters. Histopathologically, there was high acute tubular necrosis (ATN) score with strong immunostaining of caspase 3. The use of Empagliflozin significantly reduced urea and creatinine in both prophylactic and therapeutic, reduced ATN score in the prophylactic group associated with minimal staining of caspase 3 and elevated reduced glutathione. In conclusion, prophylactic Empagliflozin protected against Cisplatin-induced acute kidney injury mainly via anti-apoptotic effect.
650    12
$a cisplatina $x aplikace a dávkování $x farmakologie $x škodlivé účinky $7 D002945
650    _2
$a protinádorové látky $7 D000970
650    _2
$a nádory $x farmakoterapie $7 D009369
650    _2
$a nežádoucí účinky léčiv $7 D064420
650    _2
$a ledviny $x patologie $x účinky léků $7 D007668
650    _2
$a diabetické nefropatie $x farmakoterapie $x prevence a kontrola $7 D003928
650    _2
$a modely nemocí na zvířatech $7 D004195
650    12
$a glifloziny $x aplikace a dávkování $x farmakologie $x metabolismus $7 D000077203
650    _2
$a hypoglykemika $7 D007004
650    _2
$a nervový růstový faktor $x analýza $x účinky léků $7 D020932
650    _2
$a glutathion $x analýza $7 D005978
650    _2
$a kaspasa 3 $x biosyntéza $x účinky léků $7 D053148
650    _2
$a malondialdehyd $x analýza $7 D008315
650    _2
$a akutní poškození ledvin $x chemicky indukované $x krev $x patologie $x prevence a kontrola $7 D058186
650    _2
$a zvířata $7 D000818
650    _2
$a potkani Wistar $7 D017208
650    _2
$a mužské pohlaví $7 D008297
653    00
$a Empagliflozin
700    1_
$a Kabel, Ahmed M. $u Tanta University, Faculty of Medicine, Department of Pharmacology, Tanta, Egypt; Taif University, College of Pharmacy, Department of Clinical Pharmacy, Taif, Saudi A
700    1_
$a Elrashidy, Mohamed $u Tanta University, Faculty of Medicine, Department of Pathology, Tanta, Egypt
773    0_
$t Journal of applied biomedicine $x 1214-021X $g Roč. 17, č. 1 (2019), s. 82-90 $w MED00012667
856    41
$u https://jab.zsf.jcu.cz/pdfs/jab/2019/01/12.pdf $y plný text volně přístupný
910    __
$a ABA008 $b B 2301 $c 1249 $y p $z 0
990    __
$a 20190601070112 $b ABA008
991    __
$a 20200114174013 $b ABA008
999    __
$a ok $b bmc $g 1410863 $s 1059160
BAS    __
$a 3
BMC    __
$a 2019 $b 17 $c 1 $d 82-90 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
LZP    __
$c NLK125 $d 20200114 $a NLK 2019-30/vt

Find record

Citation metrics

Archiving options